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Abstract
Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of the lysosomal enzymes
involved in the glycosaminoglycan (GAG) breakdown pathway. This metabolic block leads to the accumulation of
GAG in various organs and tissues of the affected patients, resulting in a multisystemic clinical picture, sometimes in-
cluding cognitive impairment. Until the beginning of the XXI century, treatment was mainly supportive. Bone marrow
transplantation improved the natural course of the disease in some types of MPS, but the morbidity and mortality re-
stricted its use to selected cases. The identification of the genes involved, the new molecular biology tools and the
availability of animal models made it possible to develop specific enzyme replacement therapies (ERT) for these dis-
eases. At present, a great number of Brazilian medical centers from all regions of the country have experience with
ERT for MPS I, II, and VI, acquired not only through patient treatment but also in clinical trials. Taking the three types
of MPS together, over 200 patients have been treated with ERT in our country. This document summarizes the expe-
rience of the professionals involved, along with the data available in the international literature, bringing together and
harmonizing the information available on the management of these severe and progressive diseases, thus disclos-
ing new prospects for Brazilian patients affected by these conditions.
Key words: mucopolisaccharidoses, Hurler syndrome, Hunter syndrome, Maroteaux-Lamy syndrome, enzyme replacement therapy,
treatment guidelines.
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Mucopolysaccharidoses (MPS) are a group of inborn
errors of metabolism caused by a deficiency of specific
lysosomal enzymes that affect glycosaminoglycan (GAG)
catabolism. The accumulation of GAG in various organs
and tissues of patients affected by MPS results in a series of
signs and symptoms which make up a multisystemic clini-
cal picture. To date, eleven enzyme defects that cause seven
different types of MPS have been identified (Neufeld and
Muenzer, 2001).
The participation of a multidisciplinary team of spe-
cialized professionals is recommended for the diagnosis,
treatment, and monitoring of patients with MPS, because
these diseases are rare and exhibit multisystemic involve-
ment (Muenzer, 2004). A group of Brazilian professionals
with experience in the treatment of MPS, representing all
regions of the country, met to draft these guidelines for the
treatment of MPS I, II, and VI, for which there currently is a
specific therapy.
General Information, Clinical Picture and
Classification of MPS I, II, and VI
MPS I
Mucopolysaccharidosis type I (MPS I) is a chronic,
progressive, multisystemic lysosomal disease caused by a
deficiency or absence of activity of the -L-iduronidase
(IDUA) enzyme. Different mutations can cause variations
in IDUA enzyme activity that are associated, in part, with
the clinical variability observed over the course of the dis-
ease (Hirth et al., 2007; Pastores et al., 2007). MPS I, like
the majority of lysosomal diseases, is inherited in an auto-
somal recessive manner and has an incidence of approxi-
mately 1 in 100,000 live births for the Hurler phenotype and
up to 1 in 800,000 live births for the Scheie phenotype
(Lowry et al., 1990; Nelson, 1997; Meikle et al., 1999;
Poorthuis et al., 1999; Neufeld and Muenzer, 2001).
The most common manifestations of MPS I include a
characteristic facies, corneal clouding, macroglossia, hear-
ing loss, hydrocephaly, cardiopathy, respiratory problems,
hepatosplenomegaly, inguinal and umbilical hernia, dysos-
tosis multiplex, limited joint mobility, and cognitive im-
pairment. In addition, the accumulation of GAGs in rigid
structures and paraspinal ligaments increases the potential
for morbidity, resulting in major risks to the cervical col-
umn (Hite et al., 2000; Weisstein et al., 2004; Fuller et al.,
2005). Due to the involvement of various organs and tis-
sues, patients with MPS I frequently require surgical inter-
ventions with a high rate of complications (Ard et al.,
2005).
MPS I is commonly classified into three clinical syn-
dromes: Hurler, Hurler-Scheie, and Scheie. Because of the
high variability of MPS I and the overlapping of symptoms
in patients, it seems more appropriate to classify patients as
having the attenuated form or the severe form (Vijay and
590 Giugliani et al.
Wraith, 2005). A review of this classification is currently
under way.
Severe form (Hurler syndrome): This is the most
severe MPS I phenotype (Soliman et al., 2007), character-
ized by impaired cognitive development, progressive coar-
sening of facial features, hepatosplenomegaly, respiratory
failure, cardiac valvulopathy, recurrent otitis media, cor-
neal clouding, musculoskeletal manifestations such as joint
stiffness and contractures, and dysostosis multiplex. The
symptoms arise after birth and progress rapidly (Pastores et
al., 2007). Most of the patients with the severe phenotype
which are not submitted to a specific treatment progress to
death, on average, before the age of 10 years, due to com-
plications related to brain damage or cardiorespiratory
problems (Weisstein et al., 2004; Boelens, 2006).
Attenuated form (Hurler-Scheie syndrome): This
phenotype manifests in infancy, however with intermediate
severity when compared with the Hurler phenotype. The
somatic symptoms reduce life expectancy to the second or
third decade of life (Pastores et al., 2007; Soliman et al.,
2007). Generally, there is no cognitive impairment, but
some patients may exhibit mild learning difficulties (Bjo-
raker et al., 2006).
Scheie syndrome: This is the most attenuated form
of MPS I (Soliman et al., 2007), In which the symptoms oc-
cur later and progress slowly. Patients exhibit normal intel-
ligence and survive until adulthood (Pastores et al., 2007).
MPS II
Mucopolysaccharidosis II (MPS II or Hunter syn-
drome) is a rare genetic disease caused by deficiency of the
lysosomal enzyme iduronate-2-sulfatase (IDS). MPS II has
an incidence of approximately 0.31 to 0.71 per 100,000 live
births (Nelson, 1997; Nelson et al., 2003; Baenher et al.,
2005), and is found almost exclusively in young males be-
cause it is an X-linked condition. Recently, however, af-
fected females – with a clinical picture in many cases
similar to that of the young males – have been described
(Tuschl et al., 2005). MPS II is a chronic, progressive dis-
ease with a clinical picture similar in certain aspects to that
of MPS I: there is great variability in the clinical manifesta-
tions, including central nervous system involvement, and
can therefore be classified into a severe or “neuropathic”
form and an attenuated or “non-neuropathic” form (Martin
et al., 2008; Wraith et al., 2008).
Patients with MPS II exhibit upper respiratory tract
dysfunctions, which can be classified as obstructive or re-
strictive (Sanjurjo-Crespo, 2007; Wraith et al., 2008).
These patients also experience a greater frequency of recur-
rent respiratory infections (Martin et al., 2008). Another
frequent complication, which also occurs in the other MPS
types, is sleep apnea (Sanjurjo-Crespo, 2007; Martin et al.,
2008; Wraith et al., 2008). With respect to musculoskeletal
disorders, joint stiffness, pelvic dysplasia, and vertebral
and rib abnormalities may be present (Sanjurjo-Crespo,
2007). Bone manifestations are called “dysostosis multi-
plex” ad exhibit specific characteristics in various bones
(Martin et al., 2008). Gastrointestinal tract manifestations
include hepatomegaly, associated or not with splenome-
galy (Wraith et al., 2008). Umbilical and inguinal hernias
are frequent findings as well (Sanjurjo-Crespo, 2007; Mar-
tin et al., 2008; Schumacher et al., 2008). Most patients de-
velop recurrent otitis and virtually all will have some
degree of hearing loss (Martin et al., 2008). Dental abnor-
malities, as well as gingival hypertrophy and hyperplasia,
may also be found in these patients (Martin et al., 2008).
Cardiologic manifestations are common and are usually
observed at around 5 years of age, generally constituting
the primary cause of death (Martin et al., 2008). Ocular
manifestations include papilledema, optic nerve atrophy,
and retinal dystrophy (Anawis, 2006; Martin et al., 2008;
Schumacher et al., 2008). Patients with MPS II also exhibit
skin disorders, such as hirsutism (Wraith et al., 2008),
Mongolian spot, and papular lesions, caused by GAG de-
posits and considered typical of this type of MPS, although
not exclusive to it (Ochiai et al., 2003; Martin et al., 2008;
Wraith et al., 2008).
From a neurological point of view, about two thirds of
MPS II patients present with manifestations such as devel-
opmental delay and/or neurological regression (Schwartz et
al., 2007). These findings indicate the presence of the
“neuropathic” form of the disease. More severely affected
patients may experience seizures (Martin et al., 2008),
which sometimes manifest at the onset of the neuro-
degenerative picture. Behavioral changes, such as hyperac-
tivity, aggressiveness, and obstinacy, may also be present
in severely affected patients (Martin et al., 2008). The at-
tenuated (“non-neuropathic”) form is characterized by little
or no central nervous system involvement, with preserved
intelligence and an extended life expectancy. At times,
classification is difficult, because there are patients with in-
termediate characteristics, such as early onset of respiratory
problems, progressive upper airway obstruction, and com-
pression of the vertebral column, among other signs and
symptoms (Frossairt et al., 2007; Sanjurjo-Crespo, 2007).
Communicating hydrocephalus and spinal cord compres-
sion syndrome, as well as carpal tunnel syndrome, may also
occur (Martin et al., 2008).
MPS VI
Mucopolysaccharidosis VI (MPS VI or Maroteaux-
Lamy syndrome) is a rare autosomal recessive genetic dis-
ease caused by deficiency of the enzyme N-acetylgalacto-
samine-4-sulfatase or arylsulfatase B (ARSB). The
estimated incidence of MPS VI is 0.23 per 100,000 live
births (Baenher et al., 2005), but in Brazil preliminary data
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indicate that this incidence is higher (Coelho et al., 1997;
Albano et al., 2000).
Patients with MPS VI exhibit a wide variability of
multisystemic symptoms with a chronic and progressive
course, where primarily the skeletal and cardiopulmonary
systems, cornea, skin, liver, spleen, brain, and meninges are
affected. The somatic involvement can resemble that of in-
dividuals with MPS I, but the patients’ intelligence is usu-
ally normal. In general, patients have a short trunk and a
thoracolumbar gibbus. Ocular manifestations include cor-
neal clouding, glaucoma, pseudoglaucoma, and papille-
dema with optic atrophy in more advanced stages.
Hypoacusia is the most common otological manifestation,
generally associated with a conductive and neurosensory
component. Respiratory involvement results from extrinsic
and intrinsic alterations to the airways. A short neck, ele-
vated epiglottis, deep cervical fossa, hypoplastic mandible,
and tracheobronchomalacia contribute to the respiratory
problems. Obstructive sleep apnea is also a frequent com-
plication in MPS VI.
Although patients with MPS VI do not exhibit mental
retardation as a direct consequence of the disease, their cog-
nitive acquisitions may be impaired by the auditory and vi-
sual deficits and by the physical limitations inherent to the
disease. Physical growth and development may be normal
in the first years of life, stagnating at around six or eight
years of age (Giugliani et al., 2007). Cardiac involvement is
a significant component of this disease and is responsible
for a large part of the patients’ morbidity and mortality (Tan
et al., 1992; Dilber et al., 2002; Azevedo et al., 2004; Oudit
et al., 2007a,b). Most of the individuals with MPS VI prog-
ress to death in their 2nd or 3rd decade of life, with heart fail-
ure, often secondary to chronic respiratory obstruction, as
the primary cause (Harmatz et al., 2004).
Biochemical and Genetic Aspects
Laboratory diagnosis
A clinical suspicion of MPS constitutes grounds for
performing a urinary GAG concentration determination.
These concentrations are elevated in virtually all types of
MPS, but the occurrence of normal levels is not reason
enough to rule out this diagnosis in a patient with a sugges-
tive clinical picture. Measurement of urinary GAG concen-
trations can be done by various methods. One recom-
mended test is quantification by reaction with DMB
(dimethylmethylene blue) solution. In contact with GAGs,
DMB produces a compound whose absorbance can be mea-
sured at 520 nm, and the reaction is linear up to 70 g/dL
(De Jong et al., 1989). The results can be expressed as mg
GAGs/mg creatinine. Even though only 250 L of urine are
required for the reaction, a minimum of 2 mL should be
sent to the laboratory (may be 24-h urine or a single random
urine specimen). The urine should be kept frozen until the
GAG concentration determination is performed. GAG lev-
els in individuals with MPS are usually very elevated (three
or more times) compared to normal levels. Urinary GAG
excretion in normal individuals is higher at birth, decreas-
ing rapidly thereafter (Iwata et al., 2000); after the age of
21 years the concentration no longer changes. Therefore,
the results must be interpreted according to the reference
standards for each age bracket.
Chromatography or electrophoresis can be used to
identify which type of GAG is present in excess (e.g.,
dermatan sulfate, heparan sulfate, keratan sulfate), which
helps define which enzymes should be tested initially
(Leistner and Giugliani, 1998). A diagnosis of MPS should
be confirmed via enzyme assay, documenting the deficient
enzyme activity that is specific to each type of MPS. Any
diagnostic test should be reviewed by a professional with
experience in lysosomal diseases, since the assays are com-
plex and the results are often difficult to interpret (Muenzer,
2004).
Identification of the genotype can be important for
predicting the phenotype (and in some cases for therapeutic
decisions), for allowing genetic family counseling, and for
aiding in prenatal diagnosis. Therefore, it is necessary to
obtain the DNA of the patient and/or a family member,
which is generally extracted from blood, but may alterna-
tively be obtained from oral mucosa cells, saliva, or other
materials.
Genetic aspects
MPS I
To date, approximately 100 mutations have been
identified in the IDUA gene (Vijay and Wraith, 2005).
Among these, W402X and Q70X have been associated
with the severe form of the disease, the Hurler Syndrome
(Fuller et al., 2005). Described as null alleles, both are asso-
ciated with undetectable production of the IDUA protein
(Matte et al., 2003). Besides these, two other less common
mutations (R89Q and R89W) have been found in patients
with the attenuated phenotype (Hein et al., 2003). The rela-
tive frequency of the mutations considered to be prevalent
seems to have a different pattern in Brazilian patients, pos-
sibly due to the greater miscegenation of our population,
with implications for the molecular analysis protocols to be
used in our country (Matte et al., 2000; Pereira et al., 2008).
Although molecular tests may determine the geno-
type, clinical and laboratory tests, which are useful for con-
firming the diagnosis, are not able to detect small
differences in residual enzyme activity, thus making it im-
possible to predict the severity of the disease (Pastores et
al., 2007). Therefore, factors such as the age at onset of
symptoms and the presence of two null mutations and of
specific clinical characteristics (such as gibbus formation
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and delayed development) are important for a more precise
classification of the disease (Pastores et al., 2007).
MPS II
MPS II is the only mucopolysaccharidosis with
X-linked inheritance. The IDS gene is located at Xp28.1
and more than 300 mutations (including deletions, inser-
tions, and substitutions) have been identified so far (Li et
al., 1999). However, a significant correlation between the
type of mutation and the phenotype has not yet been estab-
lished, although patients with total or partial deletion of the
gene or with rearrangements between the gene and the
pseudogene may exhibit a more severe phenotype. More-
over, it is interesting to observe that the same mutation can
be associated with different phenotypes (Martin et al.,
2008).
MPS VI
MPS VI is inherited in an autosomal recessive man-
ner. The gene that codifies the enzyme arylsulfatase B
(ARSB) is located on chromosome 5q13-14. The panel of
mutations detected so far is fairly heterogeneous (Kara-
georgos et al., 2007), with a low relative frequency of each
mutation. Only in Portugal and in Brazil have relatively
common mutations been identified (Petry et al., 2003,
2005). A correlation between urinary GAG excretion and
the clinical phenotype has now been established (Swiedler
et al., 2005), but there is no well-established correlation yet
with the genotype of the affected individuals (Litjens et al.,
1996).
Genetic Counseling and Prenatal Diagnosis
As genetic counseling provides the family with infor-
mation regarding reproductive risks, it can contribute to-
ward preventing the recurrence of MPS I, II, and VI. The
risk of recurrence for a normal couple with a child affected
by MPS I or VI, which are inherited in an autosomal reces-
sive mode, is 25% for each new pregnancy. As in most
autosomal recessive disorders, parental consanguinity is
often present (Neufeld and Muenzer, 2001). In the case of
MPS II, an X-linked condition, identification of female car-
riers is very important since, for each pregnancy, a female
carrier has a 25% risk of having an affected child (50% risk
for a male child). In families with a prior history of one of
these types of MPS, prenatal diagnosis by means of chori-
onic villus biopsy or amniotic fluid collection during the
first or second trimester of pregnancy, respectively, can de-
tect further cases. The level of enzyme activity in the cells
(by direct study or after culturing) leads to the diagnosis.
Enzymatic diagnosis can be performed in umbilical cord
blood, but the risks of the procedure and the gestational age
at diagnosis are increased in this case. When mutations are
already known in the family, this diagnosis may be quickly
obtained by molecular analysis of the material collected
(Rogoyski et al., 1985).
Treatment
Before the advent of hematopoietic stem cell trans-
plant (HSCT) and especially of enzyme replacement ther-
apy, the main focus of the treatment of MPS I, II, and VI
was the prevention and management of complications. This
treatment was symptomatic and palliative, based on a
multidisciplinary team in which the participation of diverse
medical specialties, such as cardiology, pulmonology, an-
esthesiology, orthopedics, physiatrics, otorhinolaryngo-
logy, ophthalmology, neurosurgery, etc., has been very
important. This approach, aimed not only at providing
treatment but also at promoting health, has been very im-
portant, even after the development of specific treatments.
Physical therapists, occupational therapists, psychologists,
and speech therapists are also essential in maintaining the
health of these patients, preventing complications, and, to a
certain degree, delaying the progression of the disease
(Pastores et al., 2007).
In the 1980s, the treatment of MPS with HSCT was
proposed (Krivit, 2004; Lange et al., 2006), and in the
1990s Enzyme Replacement Therapy (ERT) was devel-
oped, providing two therapeutic tools for restoring, at least
partially, the activity of the deficient enzyme. ERT became
a reality approved for clinical use in 2003 for MPS I, in
2005 for MPS VI, and in 2006 for MPS II (Kakkis et al.,
2001a,b; Wraith et al., 2004, 2007; Harmatz et al., 2005a,b,
2008; Wraith, 2005; Muenzer et al., 2006, 2007; Sifuentes
et al., 2007; Clarke, 2008; Clarke et al., 2009; Giugliani et
al., 2009).
Hematopoietic Stem Cell Transplantation (HSCT)
HSCT has been used in patients with mucopoly-
saccharidosis for the purpose of correcting the enzyme de-
ficiency (Boelens et al., 2007). Although it is a high-risk
procedure with a high morbidity/mortality rate, many stud-
ies reveal that HSCT can, in fact, change the natural history
of the disease, increasing life expectancy and improving
many systemic abnormalities (Vellodi et al., 1997; Wraith
et al., 2007). However, its indication still depends on the
type of MPS, the patient’s clinical picture, his/her age, and
whether or not there is neurological impairment (McKinnis
et al., 1996; Aldenhoven et al., 2008; Muenzer et al., 2009).
MPS I
The main indication of HSCT is for patients with the
severe form of MPS I, because – if performed before two
years of age – it seems to favorably and significantly alter
their cognitive impairment (Boelens et al., 2007; Muenzer
et al., 2009). Age is an important factor, since in our coun-
try many patients are diagnosed only after or close to the
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age of two years. In addition, to perform HSCT, a compati-
ble donor is required, which may delay the procedure con-
siderably, also reducing the potential benefits (Muenzer et
al., 2009). Another relevant aspect is the difficulty in pre-
dicting with certainty, at the onset of the disease, which pa-
tients will develop the severe form, making it hard to
identify those for whom the risk-to-benefit ratio of HSCT
would be favorable (Fuller et al., 2005). Thus, despite inter-
national experience indicating that the potential benefit of
HSCT is superior to that of ERT in patients with the severe
form of MPS I when performed before two years of age, the
difficulties mentioned above lead to HSCT being per-
formed on a rather limited basis in Brazilian patients with
MPS I - a reality that should be changed.
HSCT can halt progression of the neurological defi-
cit, prevent premature death due to heart or liver disease,
and prolong the survival of affected children. However,
even when performed early, HSCT does not correct skeletal
deformities, despite improving odontoid dysplasia and ac-
celerating growth. Ophthalmologic abnormalities also im-
prove significantly with HSCT. Pulmonary complications
are frequent following transplantation, and their occurrence
is related to several pre-transplant risk factors. There is evi-
dence that ERT initiated around 12 weeks prior to trans-
plant may reduce respiratory complications during the
post-transplant period, which would be an indication for its
use, although the follow-up time has not yet been long
enough to permit assessment of the long-term impact of this
combination (Tolar et al., 2008). Graft-versus-host disease
(GVHD) is also reported frequently, and various strategies
have been used in the attempt to reduce this complication
that greatly alters the patients’ quality of life. The results of
the transplants performed more recently show significant
progress with this procedure and a survival rate of over
70% (Staba et al., 2004; Boelens et al., 2007; Aldenhoven
et al., 2008; Prasad et al., 2008), however the rates obtained
in the northern hemisphere cannot be automatically ex-
tended to Brazil, due to the different local conditions.
MPS II
To date, the results of bone marrow transplants
[BMT] in patients with MPS II have not been considered
satisfactory (Martin et al., 2008; Wraith et al., 2008). How-
ever, encouraging developments have now been reported
with HSCT performed very early in a limited number of
MPS II patients (Martin et al., 2006; Prasad et al., 2008). In
general, this therapy has not been recommended for these
patients, due to the lack of clearly demonstrated neurologi-
cal benefits and the high rate of morbidity and mortality
(Zareba, 2007).
MPS VI
BMT is considered a therapeutic alternative for MPS
VI (Herskhovitz et al., 1999), but ever since the introduc-
tion of ERT it has been relegated to a second place, because
the risks of HSCT do not appear to exceed the benefits in
this type of MPS, once patients do not have a cognitive def-
icit, and the systemic problems have responded satisfacto-
rily to ERT without the risks of BMT (Giugliani et al.,
2007).
Outline of the transplantation protocol
A patient with an indication for transplantation (in
general, a patient under two years of age with the severe
form of MPS I) should be referred to a BMT/HSCT refer-
ence unit capable of performing this type of procedure in
these patients. Transplant shall be indicated only after a
careful evaluation with respect to the basic disease and to
prior complications, primarily pulmonary and neurological
ones. A suitably compatible donor may be found among the
members of the family or in national and international vol-
unteer donor banks. Donors with greater compatibility and
higher enzyme concentrations will be preferentially se-
lected. The patient will undergo the protocol in use in the
reference department. Following the infusion of stem cells,
all supportive care measures will be maintained until the
graft takes. During the severe pancytopenia period, broad-
spectrum antibiotics, transfusions of irradiated blood prod-
ucts, total parenteral nutrition, and water-electrolyte re-
placement will be used. One month after the infusion of
stem cells, graft acceptance will be confirmed by complete
blood count, molecular biology techniques, and enzyme
evaluation. The patient will be followed regularly at the
transplant unit by means of enzyme concentration determi-
nations, evaluation of graft acceptance, and monitoring
with respect to post-transplant complications.
Enzyme Replacement Therapy (ERT)
Enzyme replacement therapy (ERT) is a treatment
that consists of the periodic intravenous administration of
the specific enzyme that is deficient in the patient. The first
effective treatment with ERT performed in patients with
Gaucher disease (Barton et al., 1990) led to the search for a
similar treatment for other lysosomal storage diseases. The
first mucopolysaccharidosis treated with ERT was MPS I
(Biomarin Pharmaceutical Inc), with ERT being subse-
quently approved for MPS VI (Biomarin Pharmaceutical
Inc) and for MPS II (Shire HGT).
MPS I
ERT for MPS I is performed by intravenous adminis-
tration of laronidase, a protein analogous to human
-iduronidase produced by genetic engineering in a Chi-
nese hamster ovary (CHO) cell expression system (Krivit,
2004). ERT with laronidase was approved for the treatment
of patients in the United States in 2003 (Food and Drug Ad-
ministration – FDA), in Europe in 2003 (European Medi-
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cines Agency – EMEA), and in Brazil in 2005 (National
Health Surveillance Agency – ANVISA).
Preclinical studies
Studies using the canine model of MPS I showed that
intravenous administration of -L-iduronidase exhibits so-
matic distribution and is able to reduce lysosomal accumu-
lation in various tissues, with a decrease in liver GAG
accumulation and in urinary GAG excretion after two
weeks (Kakkis, 2002).
Clinical studies
Phase I/II - Ten patients ranging in age from five to
22 years received 0.58 mg/kg of -L-iduronidase intrave-
nously once a week for 52 weeks (Kakkis et al., 2001a).
Summary of the main study findings: (a) Hepato-
megaly decreased significantly in all patients and liver size
normalized in eight of the 10 patients as early as in the 26th
week; (b) The height and weight growth rate increased by
an average of 85% and 131%, respectively, in the 52nd week
in six prepubescent patients; (c) The mean maximum mo-
tion range of shoulder flexion and elbow extension in-
creased significantly; (d) The number of sleep apnea and
hypopnea episodes decreased by 61%; (e) Heart function
(evaluated by The New York Heart Association functional
classification) improved by one or two classes in all pa-
tients; (f) Urinary GAG excretion decreased after three or
four weeks of treatment; (g) Serum anti--L-iduronidase
antibodies were detected in four patients.
Phase II/III - A randomized, double-blind, placebo-
controlled, multinational study was performed, including
45 patients with MPS I (one with Hurler, 37 with Hurler-
Scheie, and seven with Scheie), randomized to receive
0.58 mg/kg of either laronidase or placebo intravenously
once a week for 26 weeks (Wraith et al., 2004).
Summary of the main study findings: (a) After
26 weeks of treatment, the patients who received laronidase
showed a mean improvement of 5.6 percentage points in
the predicted normal Forced Vital Capacity (FVC) (median
3.0; p = 0.009) and 38.1 meters of distance in the Six-
Minute Walking Test (6MWT) (median 38.5; p = 0.066;
p = 0.039, analysis of covariance); (b) The use of laronidase
also significantly reduced hepatomegaly and urinary GAG
excretion; (c) In the more severely affected patients there
was improvement in apnea/hypopnea and shoulder flexion;
(d) Laronidase was well tolerated and practically all pa-
tients receiving the enzyme developed IgG antibodies, with
no apparent clinical effect.
Phase IV - A prospective, open-label, multinational
study that included 20 children (16 with Hurler syndrome
and four with Hurler-Scheie syndrome), all under five years
of age. All patients received intravenous treatment with
0.58 mg/kg or 1.16 mg/kg laronidase weekly for 52 weeks
(Wraith et al., 2007).
Summary of the main study findings: (a) Tolerance to
laronidase was good with both dosages; (b) GAG levels de-
creased by approximately 50% in the 13th week of treat-
ment and 61.3% in the 52nd week; (c) The liver edge
decreased by 69.5% on palpation in those patients with a
palpable liver at the time the study started; (d) The propor-
tion of patients with left ventricular hypertrophy decreased
from 53% to 17% in the 52nd week; (e) A global assessment
of the sleep studies revealed improvement or stabilization
in 67% of the patients; (f) The apnea/hypopnea index de-
creased by 5.8 events per hour.
MPS II
ERT for the treatment of MPS II is performed by in-
travenous administration of idursulfase, a glycosylated pro-
tein analogous to native human iduronate-2-sulfatase,
produced by genetic engineering in a continuous human
cell line (Muenzer et al., 2007). ERT with idursulfase was
approved for the treatment of patients in the United States
in July 2006 (FDA), and in Europe in January 2007
(EMEA). In Brazil, registration with ANVISA occurred in
2008.
Preclinical studies
The animal model used for MPS II was a mouse
(IdS-KO) whose IDS gene had been modified by genetic
engineering techniques. The study performed by Muenzer
et al. (2002) demonstrated that IdS-KO mice already exhib-
ited increased urinary GAG excretion at six weeks of age,
and at 10 weeks of age they showed evidence of skeletal
and facial abnormalities. GAG accumulation in the liver,
kidneys, lungs, and heart valves was evident at all ages.
Weekly doses of idursulfase (0.5 mg/kg) reduced urinary
GAG excretion in these mice after the third infusion. The
reduction in GAG in the liver, kidneys, heart, spleen, lungs,
skin, and skeletal musculature was more pronounced in the
animals treated with the 1 mg/kg dose. Another study (Gar-
cia et al., 2007) indicated that doses given weekly or every
two weeks reduced urinary GAG excretion and hepato-
megaly in the animals tested. These studies demonstrated
that idursulfase was effective in reducing the level of GAGs
in urine and tissue in mice.
Clinical studies
Phase I/II - A double-blind study that included 12 pa-
tients aged 5 years or older, divided into three treatment
groups. The groups received infusions of idursulfase every
two weeks, at the following doses: 0.15, 0.50, and
1.50 mg/kg. The study duration was 27 weeks (Muenzer et
al., 2007).
Summary of the main study findings: (a) All patients
treated with idursulfase, regardless of the dose, showed a
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reduction in mean urinary GAG excretion following the
first infusion, with a faster decrease in the groups receiving
the 0.5 and 1.5 mg/kg doses; (b) A reduction in liver and
spleen volume occurred; (c) A significant increase in walk
test distance (p = 0.013) was observed in the groups that re-
ceived 0.50 and 1.50 mg/kg of idursulfase; (d) One year of
treatment with idursulfase was well tolerated; (e) IgG anti-
bodies were detected in 6/12 patients (three in the group
that received 0.5 mg/kg and three in the group that received
1.5 mg/kg). The development of antibodies did not have
any clinical or biological impact on idursulfase activity.
None of the patients developed anti-idursulfase IgE anti-
bodies.
Phase II/III - An international, multicenter study that
included 96 patients ranging from five to 31 years of age,
divided into three groups: placebo, idursulfase (0.5 mg/kg)
once a week, and idursulfase (0.5 mg/kg) every two weeks.
The duration of the study was 53 weeks. Randomization
was stratified by age and by disease score at baseline
(6MWT and FVC%) (Muenzer et al., 2006).
Summary of the main study findings: (a) The com-
bined variable (FVC% and 6MWT) score was significantly
higher in the groups that received idursulfase; (b) After
53 weeks of weekly idursulfase infusions, the 6MWT dis-
tance increased significantly; (c) The predicted FVC in-
creased in patients who received idursulfase weekly; (d)
With respect to absolute FVC, there was a significant in-
crease in the weekly idursulfase group; (e) Liver volume
decreased by more than 20% after 18 weeks of treatment in
both groups that received idursulfase; (f) About 80% of pa-
tients with hepatomegaly exhibited normal liver volume at
between 18 and 53 weeks of treatment; (g) After 18 weeks
of treatment, spleen volume decreased by approximately
20% to 25% in the groups that received idursulfase weekly
and every other week, respectively; (h) After 53 weeks,
spleen volume remained significantly reduced in the
groups treated with idursulfase; (i) At week 53, GAG levels
in the idursulfase groups were significantly lower. After
53 weeks of treatment, regardless of the idursulfase dosing
regimen, 26/64 patients (40.6%) exhibited normal urine
GAG levels, and the majority of patients were close to nor-
mal limits; (j) An improvement in elbow joint mobility was
observed; (k) One year of treatment with idursulfase was
well tolerated; (l) IgG antibodies were detected in 15 pa-
tients in the group that received idursulfase weekly and in
15 patients of the group that received idursulfase every two
weeks; (m) IgM antibodies occurred in two patients, one in
each idursulfase treatment group; (n) There was no impact
on the central nervous system.
MPS VI
ERT for the treatment of MPS VI is performed by in-
travenous administration of galsulfase, a recombinant form
of the enzyme N-acetylgalactosamine 4-sulfatase,
synthesized by means of genetic engineering from Chinese
hamster ovary cells (Fuller et al., 1998; Auclair et al., 2003;
Harmatz et al., 2008). The marketing and use of galsulfase
was approved in the United States in 2005 (FDA), in the
European Union in January 2006 (EMEA), and was regis-
tered with ANVISA in February 2009.
Preclinical studies
Studies using an experimental model of MPS VI
(cats) showed that administration of galsulfase produced a
significant improvement in some signs of the disease (Bie-
licki et al., 1999; Turner et al., 1999; Kakkis, 2002; Auclair
et al., 2003). They also showed a decrease in GAG storage
in organs, an increase in joint mobility, and prevention or
slowed progression of skeletal disease.
Clinical studies
Phase I/II - The study by Harmatz et al. (2005b) was
performed in six patients, using two different doses of the
drug, 1 mg/kg and 0.2 mg/kg, given in weekly infusions
during 48 weeks.
Summary of the main study findings: (a) The drug
was well tolerated; (b) There was a reduction in GAG ex-
cretion via the urine.
Phase II - The study, performed in 10 patients, used
the 1 mg/kg dose established in the previous study for 48
weeks, with weekly intravenous infusions (Harmatz et al.,
2005a).
Summary of the main study findings: (a) Confirma-
tion of the results of the phase I/II study; (b) Improvement
in the ability to climb stairs; (c) Improvement in the 12-mi-
nute walk test; (d) Feeling of improvement in joint stiffness
and pain.
Phase III - The study used the same dose and admin-
istration method as the phase II study, but now with 39 pa-
tients for 24 weeks (Harmatz et al., 2006).
Summary of the main study findings: (a) Confirma-
tion of the results of the previous study; (b) Improvement in
general resistance measured by means of the 12-minute
walk test, and in the ability to climb stairs; (c) Reduction in
urine GAG excretion; (d) Of the 54 patients who partici-
pated in these studies, only one did not develop specific an-
tibodies to galsulfase.
Guidelines For Enzyme Replacement Therapy
MPS I
The laronidase prescribing information approved by
FDA (NDC 58468-70070-1) and EMEA in 2003, and regis-
tered in Brazil (ANVISA) in 2005, states that laronidase is
indicated for patients with the Hurler and Hurler-Scheie
forms of mucopolysaccharidosis type I and for patients
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with the Scheie form who exhibit moderate to severe symp-
toms. In Latin America, the only country that has currently
published a consensus on the diagnosis and treatment of
MPS I is Argentina (Argentine Pediatrics Society, 2008).
The inability of intravenously administered laroni-
dase to reach the central nervous system, at least at the cur-
rently recommended dose of 0.58 mg/kg per week, limits
its effects on neurological impairment in patients with the
severe and neurodegenerative form of the disease (Hurler
phenotype), therefore being indicated for the treatment of
non-neurological symptoms of the disease.
The use of ERT in association with HSCT has not yet
been established, although there is evidence that this com-
bination reduces pulmonary complications following trans-
plant (Tolar et al., 2008). To date, the primary justification
for defending the use of ERT in patients in whom HSCT is
indicated is to improve the patient’s physical condition
while a compatible donor is sought (Wraith, 2001).
Objectively, ERT should be indicated in the follow-
ing cases in which there is a confirmed diagnosis of MPS I:
Patients of any age who are symptomatic and who exhibit at
least one clinical manifestation that responds to treatment
with ERT. These manifestations may be: (a) Respiratory
diseases, such as upper airway obstructions, recurrent in-
fection, restrictive diseases; (b) Cardiac disorders, such as
cardiomyopathy and valve disease; (c) Osteoarticular dis-
orders that impair locomotion or make it difficult, causing
the patient to be dependent on other people for carrying out
every-day activities; (d) Sleep apnea with an apnea index
(AI) higher than one event/h of sleep for patients under
17 years of age, and higher than 5 events/h of sleep for
adults; (e) Mean nocturnal O2 saturation < 92% in children
and < 85% in adults; (f) Patients which are hard to intubate.
Drug characteristics and Usage Regimen (dose, fre-
quency, and infusion time) for MPS I are presented in
Table 1.
A recent study (Giugliani et al., 2009) indicated that
the administration of a double dose every other week does
not result in significant disadvantages to the patient, and
this administration regimen may be considered in cases in
which a weekly infusion regimen is difficult to implement
for some operational or logistical reason.
MPS II
ERT can be performed in all symptomatic patients
with a confirmed MPS II diagnosis. Although Wraith et al.
(2008) suggested that patients with significant CNS in-
volvement should receive ERT for 12 to 18 months, and
maintenance of ERT should be assessed after this period,
the overall benefits of this treatment are questionable in pa-
tients with severe impairment of cognitive functions, since
the intravenously administered enzyme does not cross the
blood-brain barrier.
Objectively, ERT should be indicated in the follow-
ing cases with a confirmed diagnosis of MPS II: Patients of
any age who are symptomatic, who do not have severe cog-
nitive impairment, and who exhibit at least one clinical
manifestation that responds to treatment with ERT: (a) Re-
spiratory diseases, such as upper airway obstructions, re-
current infections, restrictive diseases; (b) Osteoarticular
disorders that impair locomotion or make it difficult, caus-
ing the patient to be dependent on other people for carrying
out every-day activities; (c) Sleep apnea frequency higher
than one event/h for patients under 18 years of age, and
higher than 5 events/h for adults; (d) Mean nocturnal O2
saturation < 92% in children and < 85% in adults.
Although ERT has not been tested in clinical trials
with patients under the age of 5 years, it has been used in
small children in isolated cases, with no indications that the
safety and efficacy profile are different from those ob-
served in older children.
Drug characteristics and Usage Regimen (dose, fre-
quency, and infusion time) for MPS II are presented in Ta-
ble 1.
MPS VI
ERT may be administered to all symptomatic patients
with a confirmed diagnosis of MPS VI, and is recom-
mended as treatment of choice for this condition. Studies
have demonstrated improvement in the walking test and in
the ability to climb stairs (Harmatz et al., 2006; Giugliani et
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Table 1 - Characteristics of the Drug and Usage Regimen (dose, frequency, and infusion time) for MPS I., MPS II and MPS VI.
Mucopolysaccharidosis I Mucopolysaccharidosis II Mucopolysaccharidosis VI
Drug and manufacturer Aldurazyme® (Genzyme Corporation) Elaprase® (Shire HGT) Naglazyme® (BioMarin Pharmaceuti-
cals)
How supplied Vials containing 2.9 mg/5 mL
(0.58 mg/mL)
Vials containing 6 mg/3 mL
(2 mg/mL)
Vials containing 5 mg/5 mL
(1 mg/mL)
Standard dose and route of
administration
0.58 mg/kg, intravenously 0.50 mg/kg, intravenously 1 mg/kg, intravenously
Frequency Weekly (7  3 days) Weekly (7  3 days) Weekly (7  3 days)
Infusion time Approximately 3-4 h From 1 to 3 h A minimum of 4 h
al., 2007), improvement in MPS VI-related bone disease,
as well as improvement in growth pattern in a patient
treated as of the eighth week of life (McGill et al., 2009). It
is known, however, that some tissues, such as the cornea,
due to their reduced perfusion, and the central nervous sys-
tem, due to the blood-brain barrier, are not significantly af-
fected by the action of the intravenously administered
enzyme (Giugliani et al., 2007; Clarke, 2008).
Objectively, ERT should be indicated in the follow-
ing cases with a confirmed diagnosis of MPS VI: Patients
of any age who are symptomatic and have at least one clini-
cal manifestation that responds to treatment with ERT.
These manifestations may be: (a) Respiratory diseases,
such as upper airway obstructions, recurrent infections, re-
strictive diseases; (b) Osteoarticular disorders that impair
locomotion or make it difficult, causing the patient to be de-
pendent on other people for carrying out every-day activi-
ties; (c) Sleep apnea frequency higher than 1 event/h for
patients under 18 years of age, and higher than 5 events/h
for adults; (d) Mean nocturnal O2 saturation < 92% in chil-
dren and < 85% in adults; (e) Patients who are hard to
intubate.
Drug characteristics and Usage Regimen (dose, fre-
quency, and infusion time) for MPS VI are presented in Ta-
ble 1.
Other Information Common To The Handling,
Preparation, and Administration of Laronidase,
Idursulfase, and Galsulfase
Usage Regimen - (a) Use of the standard dose is rec-
ommended. Some small adjustments may be made, as long
as the dose used does not vary more than 10% in relation to
the standard dose. Similarly, the final monthly dose should
not vary more than 10% with regard to the ideal monthly
dose, established according to the standard dose. (b) Dose
calculation should be reviewed every three months, whe-
ther the patients are children or adults. (c) It is recom-
mended that the infusion be initially administered in a
hospital environment and preferably in a bright environ-
ment that is pleasant for the patient. Given the increasing
number of patients throughout the country who are receiv-
ing ERT, it is recommended that this procedure be stan-
dardized within the Brazilian Integrated Health System
(SUS), so as to become one of the procedures officially
considered to be performed in a “day hospital” setting. (d) It
is important to alternate the peripheral vein puncture sites.
Whenever a totally implanted central catheter is used, use
of EMLA® is recommended (1 h or 1 h 30 min pre-punc-
ture). (e) The patient should be observed for at least 1 h af-
ter the end of the infusion, at least during the first three
months of treatment, if it is not possible to do so for the
ideal period, which is six months. After this observation pe-
riod, if there is no complicating factor, the patient may be
released immediately following the infusion.
Contraindications - ERT is not indicated for women
who are pregnant or nursing, unless it is absolutely essen-
tial. Terminal patients should not receive ERT either, nor
should patients with a severe concomitant disease, the
prognosis of which will not change as a result of the ERT.
Premedication - Possible infusion reactions are very
specific to each patient, so the physician should assess the
need for premedication and its strength on a case-by-case
basis. Premedication with antipyretics and/or antihista-
mines is generally used for ERT in patients with MPS I. For
patients with MPS VI receiving ERT, antihistamines have
been used, with or without antipyretics, about 1 h prior to
the start of the infusion. If there is an infusion reaction that
persists even with the use of antipyretics and antihista-
mines, the use of corticosteroids prior to ERT should be
considered, e.g., prednisolone (1 mg/kg), 12 h and 1 h be-
fore the infusion. The use of premedication is not routinely
prescribed in MPS II patients receiving ERT, except for
preventing recurrence of infusion reactions.
Drug Preparation - Using proper asepsis techni-
ques, the drug should be prepared as follows: (a) Determine
the number of vials to be diluted, based on the patient’s
weight and the standard recommended dose of the replace-
ment enzyme, adjusting it in such a way that whole vials are
used; (b) Remove the vials from the refrigerator, to allow
them to reach room temperature. These vials should not be
heated; (c) The solution is transparent or somewhat yellow-
ish, and clear or slightly opalescent, as some transparent
particles may be present. If these characteristics of the solu-
tion are altered, these vials should not be used; (d) Deter-
mine the total final volume to be infused, which depends on
the patient’s weight and the drug to be prepared: MPS I:
100 mL (weight  20 kg) or 250 mL (weight > 20 kg); MPS
II: 100 mL (for all weights) plus the total calculated volume
of idursulfase; MPS VI: 250 mL (in general – for weights
less than or equal to 20 kg; in patients who are susceptible
to volume overload, the physician may consider the total
volume of 100 mL); (e) Slowly aspirate the calculated vol-
ume of enzyme from the vials, taking care not to shake the
solution, since shaking can denature the product and render
it biologically inactive; (f) From the corresponding bag of
physiological saline solution (100 mL or 250 mL), remove
a volume equal to that calculated and aspirated from the vi-
als of enzyme, so that, after adding the volume of enzyme,
the total final volume of 100 mL or 250 mL, is reconstituted
(this step is not necessary for idursulfase, since the orienta-
tion in the prescribing information is to dilute the total cal-
culated volume of idursulfase in 100 mL of 0.9% Sodium
Chloride Injection); (g) The addition of the enzyme solu-
tion to the bag of physiological saline solution has to be
slow, and the bag containing the final solution has to be ro-
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tated gently, to permit homogeneous distribution of the
drug; (h) This solution should be used immediately. If im-
mediate use is not possible, the solution must be stored un-
der refrigeration (2 °C to 8 °C) for a maximum period of
36 h from preparation to the end of administration of the so-
lution (24 h for idursulfase, according to the Brazilian prod-
uct information). Do not leave the prepared solution at
room temperature; (i) In the case of MPS I, the use of albu-
min is recommended in the United States, but it is not used
in the European countries. In Brazil, the ANVISA-
approved prescribing information also recommends its use.
However, the experience of Brazilian specialists indicates
that the use of albumin can be dispensed with.
Infusion Rate - After preparation of the drug, the in-
fusion should be administered in an incrementally increas-
ing manner as recommended below. However, in the event
of reactions associated with the infusion, these incremen-
tally increased rates and the final maximum rate reached
may be modified according to each patient’s tolerance.
MPS I: (a) Weight less than or equal to 20 kg (total
volume 100 mL): 2 mL/h x 15 min; 4 mL/h x 15 min;
8 mL/h x 15 min; 16 mL/h x 15 min; 32 mL/h x ~3 h; (b)
Weight more than 20 kg (total volume 250 mL): 5 mL/h x
15 min; 10 mL/h x 15 min; 20 mL/h x 15 min; 40 mL/h x
15 min; 100 mL/h x ~3 h.
MPS II: 8 mL/h x 15 min; 16 mL/h x 15 min; 24 mL/h
x 15 min; 32 mL/h x 15 min; 40 mL/h x ~2 h. This rate may
be increased by 8 mL/h x 15 min, without exceeding the
maximum rate of 100 mL/h.
MPS VI: 6 mL/h x 1 h; 80 mL/h x ~3 h.
Use of Filters - It is recommended that the adminis-
tration of laronidase, idursulfase, and galsulfase solution be
performed using an infusion set with a 0.2 m filter.
Adverse Reactions – Conduct - The infusion reac-
tions most commonly reported with the use of ERT were:
pyrexia, headache, abdominal pain, dyspnea, chills, arthral-
gia, pruritus, hypertension/hypotension, urticaria, and
exanthema (rash). If an infusion reaction occurs, regardless
of whether premedication was used, the following mea-
sures should be taken, in this order, until the symptoms
improve: reduction of the infusion rate, temporary discon-
tinuation of the infusion, additional administration of anti-
pyretics and antihistamines.
If a severe hypersensitivity reaction or an anaphyl-
actic reaction occurs, the infusion should be stopped imme-
diately and appropriate supportive measures should be
promptly taken, according to the picture presented. The use
of corticosteroids and airway and venous access mainte-
nance measures may be necessary, and resuscitation mea-
sures must be implemented in extreme cases. For this
reason, it is recommended that the infusion center should
have the equipment necessary for comprehensive care of
cardiorespiratory arrest (crash cart) and have easy access to
the emergency room.
If the use of epinephrine is considered, it should be
used with extreme caution, due to the increased prevalence
of coronary disease in many patients with MPS.
The risk-to-benefit ratio of enzyme administration
following a severe hypersensitivity reaction or anaphyl-
actic reaction should be evaluated and, if ERT infusions are
reinitiated, appropriate resuscitation measures should be
available for use in extreme cases.
Ideally, before initiation of ERT, blood should be
drawn for antibody level determination. This sample shall
be kept until this determination is necessary, i.e., in the
event the patient experiences an infusion reaction. If the pa-
tient does experience an infusion reaction, blood should be
drawn again between 1 and 2 h from the onset of the reac-
tion, or according to the enzyme manufacturer’s directions.
Adverse Reactions – Pharmacovigilance - Any
side-effect should be reported as soon as possible to the
Pharmacovigilance Department of ANVISA and to the
pharmacovigilance section of the hospital, if applicable. In
addition, the companies responsible for the drugs laro-
nidase (Genzyme), idursulfase (Shire/HGT), and galsulfase
(BioMarin) request that they be notified via their medical
departments, for pharmacovigilance purposes.
Clinical Routine - Before the start of each infusion, a
brief history should be taken and a targeted physical exami-
nation, including the checking of vital signs, should be per-
formed. The collection of samples for monitoring tests may
be indicated. Patients do not need to be fasting nor have
their diets modified because of the infusion.
Criteria for Discontinuation of Treatment - To
date, there are no established criteria determining the indi-
cation for discontinuation of treatment, however it is rec-
ommended that ERT be discontinued: (a) During
pregnancy and breastfeeding; (b) In patients who, despite
ERT, have progressed to terminal disease or experience a
significant worsening of their clinical parameters, mea-
sured at least every six months and preferably over a period
of at least 12 months of ERT; (c) In patients who do not ex-
hibit any measurable clinical benefit, taking into consider-
ation the natural rate of progression of the disease, based on
parameters measured at least every six months and prefera-
bly over a period of at least than 12 months of ERT.
The possibility of discontinuation of treatment should
be mentioned to the parents/patient or legal guardians when
ERT is being considered and prior to its initiation. During
clinical monitoring of a patient receiving ERT, the ERT
therapeutic response parameters should be evaluated peri-
odically and discussed with the parents/patient or legal
guardians. If discontinuation of ERT is being considered,
this should be discussed with the parents/patient or legal
guardians.
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When temporary suspension of ERT is considered, it
should be taken into account that the few reports on ERT in-
terruption found in the literature show that discontinuation
of this treatment can lead to a rapid deterioration of the pa-
tient’s clinical picture (Anbu et al., 2006; Wegrzyn et al.,
2007).
Presymptomatic Treatment - Although there are
fairly encouraging results, the benefits of presymptomatic
treatment observed in various case reports have not yet
been assessed via clinical trials (which are currently under
way in the case of MPS VI). Thus, in cases in which the
physician considers it to be indicated, the treatment of MPS
I, MPS II, and MPS VI prior to the onset of symptoms
should be presented to the family as an experimental proce-
dure, and it is suggested that an Informed Consent Form ap-
proved by the competent ethical bodies be utilized.
Treatment in Children Under Five Years of Age -
The use of laronidase in children under five years of age has
been shown to be safe, as demonstrated in a specific clinical
study in small children with MPS I (Wraith et al., 2007).
This favorable result in terms of safety has also been con-
sistently observed in several cases of young MPS II and
MPS VI patients treated with ERT (Kim et al., 2008), al-
though it has not yet been formally assessed in small chil-
dren via clinical trials.
Alternative Routes of Administration - Brazil was
a pioneer in the intrathecal administration of recombinant
enzyme in a patient with MPS I, for treatment of spinal cord
compression. This experience had encouraging results and
was reported in the literature (Muñoz-Rojas et al., 2008).
Additional cases of Brazilian patients with MPS and spinal
cord compression (one with MPS I and another with MPS
VI) were similarly treated and the reports are being pre-
pared for publication. However, intrathecal administration
of the enzyme should be considered an experimental proce-
dure for the time being.
Home Infusion - Home infusion may constitute an
option for patients who, after three to six months of hospital
infusion, have not experienced any significant infusion re-
actions. It is recommended that both the infusion location
and the drug storage and preparation location be approved
by the person in charge of the reference center’s medical
staff, and that a professional nurse trained for this specific
procedure monitor the infusion all the time and regularly
inform the reference center about the procedure. The pa-
tient undergoing home infusion must have regular medical
checkups at the reference center at least every three months
(Cox-Brikman et al., 2007).
Prospects and Conclusions
The authors of this study are convinced that a better
future for patients suffering from mucopolysaccharidoses
depends on the proper identification, understanding and
management of the multisystemic manifestations of these
diseases, including supportive measures (which should be
part of the regular multidisciplinary care of these patients)
and specific therapies. There are indications that earlier de-
tection and treatment of patients, possibly by means of
newborn screening, may contribute to a better prognosis. A
definitive cure may perhaps be achieved through gene ther-
apy, but this moment could still take some time to arrive.
Although inhibition of glycosaminoglycan synthesis
and the restoration of enzyme activity with small molecules
may also come to play a role in the management of MPS,
the main advance currently available is ERT. Along with
HSCT (for specific situations), ERT has enabled a radical
change in the panorama of treatment for mucopoly-
saccharidosis I, II, and VI in the past decade and is helping
to provide a better understanding of the physiopathology of
the disease (Pereira et al., 2008) and potential biomarkers
(Randall et al., 2008). It is further possible that its benefits
may be extended to MPS IV A shortly, with prospects for
the treatment of MPS III A and of the cognitive deficit in
MPS II via administration of the enzyme directly into the
central nervous system (CNS).
Presently, a large number of Brazilian centers, includ-
ing departments in all regions of the country, have already
some experience with ERT for MPS I, II, and VI, acquired
not only by treating patients, but also through the participa-
tion of some groups in clinical trials involving ERT for
these conditions. Taking the three types of MPS together,
over 200 patients have been treated with ERT in our coun-
try so far. The experience of professionals, along with the
data available in the international literature, enabled the
drafting of this document, produced with the purpose of
joining and harmonizing the information available on the
treatment of these severe and progressive diseases, which
are, fortunately, treatable today, offering new prospects for
Brazilian patients affected by these conditions.
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Note about the steps followed for the drafting of this document
For the drafting of this document, the following steps
were performed:
1) Collection of Initial Data and Drafting of the
Preliminary Document:
This phase was carried out at the Medical Genetics
Service [SGM] of the Porto Alegre Clinical Hospital
[HCPA (Hospital de Clínicas de Porto Alegre)]. Six mem-
bers of the SGM/HCPA mucopolysaccharidosis staff, sug-
gested by Prof. Roberto Giugliani, were invited and agreed
to take part in the following teams:
- MPS I – Verónica Muñoz and Andressa Federhen
- MPS II – Louise Pinto and Taiane Vieira
- MPS VI – Ana Cecília Azevedo and Osvaldo Arti-
galás
A systematic review of the literature along with the
PubMed and Bireme databases was initially performed.
The following keywords were used for the search:
• Mucopolysaccharidoses
• Mucopolysaccharidosis I
Hurler syndrome
Scheie syndrome
Hurler-Scheie syndrome
• Mucopolysaccharidosis II
Hunter syndrome
• Mucopolysaccharidosis VI
Maroteaux-Lamy syndrome
Enzyme replacement therapy
Natural history
Treatment
Clinical trial
Surveys & Registries
Also included were articles accepted for publication
and articles that contained information relevant to the draft-
ing of the document, even if the keywords did not appear in
them. From the articles collected, a text on MPS I, MPS II,
and MPS VI was drafted following the outline below:
a) Brief summary on each disease, covering:
– clinical picture
– natural course, including most common complica-
tions
– inheritance and incidence
– biochemical and molecular defect
– diagnostic process
– conventional treatments
– prevention (detection of carriers, genetic counsel-
ing, and prenatal diagnosis)
b) Enzyme Replacement Therapy
– history (preclinical studies)
– summary of clinical trials (phases I, II, and III)
– summary of the experience to date
– guidelines for ERT:
– indications
– usage regimen (frequency, dose, infusion time)
– premedication
– preparation of the drug
– instructions regarding filters
– adverse reactions – conduct
– adverse reactions – pharmacovigilance
– clinical routines for the patient receiving ERT
– periodic evaluations
– criteria for discontinuation of treatment
– effect of discontinuation of treatment
2) Evaluation by Brazilian Specialists and
Production of a Consolidated Document:
After the preliminary document was drafted, it was
sent by e-mail to a group of Brazilian professionals from all
the five regions of the country with experience in the mat-
ter, including representatives of medical societies with an
interest in the area, in order for them to become acquainted
with it.
A workshop was then organized which these special-
ists were invited to, for a general discussion of the docu-
ment. This meeting was held in Caxias do Sul, on May 16,
17, and 18, 2008, with over 40 members of the group pres-
ent.
Each topic of the document was discussed and the
suggestions were recorded by the main writing team and by
a medical writing specialist who was added to the group. A
consolidated document was then prepared and sent to the
group members, who made further suggestions, which
were incorporated into this version.
3) Prospects for Revision of the Document
Throughout the process of drafting this document,
various suggestions for improving it came up, which will be
the subject of a new round of discussion, aiming to the pro-
duction of a second version. Among these are:
a) drafting of protocols for the diagnosis of patients
with MPS;
b) drafting of protocols for the treatment of these con-
ditions;
c) drafting of clinical and laboratory protocols for pa-
tient evaluation and follow-up;
d) drafting of a checklist with minimum criteria and
recommended criteria for the setting-up of an en-
zyme replacement therapy infusion center for
MPS;
e) establishment of objective criteria for discontinua-
tion of treatment;
f) inclusion of a directory of professionals and de-
partments experienced in the diagnosis and treat-
ment of these diseases in different locations in
Brazil;
g) discussion and drafting of a sample Informed Con-
sent Form for use in specific cases that do not meet
the usual inclusion criteria;
h) a general review, possible adoption of a new for-
mat, and updating of the document in light of new
evidence that has appeared in the literature and the
growing experience of the professionals participat-
ing in the group.
